The company said that it plans to use funds from its recent $18 million Series B round to drive instrument sales and develop AI tools for data analysis.
Investors included Bruker, whose MALDI mass spectrometry imaging platforms could have synergies with Ionpath's Multiplexed Ion Beam Imaging technology.
The firm said it would use the funding to grow its client base and further R&D programs using machine learning for biomarker discovery and precision medicine.
The Wilmington, Delaware-based startup will use the funds for clinical validation trials on its Arna Breast cancer diagnostic test in the US and Europe.
The funding will allow the company to accelerate development of its DNA synthesis technology, hire staff, build an R&D facility, and establish industrial partnerships.
The financing will be used for the development and clinical validation of oncology panels for treatment selection and patient monitoring with an initial focus on NSCLC.
Howard Hughes Medical Institute will be requiring its researchers to publish their work so it is immediately accessible to the public, ScienceInsider writes.
About 150 million rapid coronavirus tests purchased by the US federal government are to be distributed to nursing homes, colleges, and the states, according to the New York Times.
